Detailed data from a key trial of Biogen Idec Inc's experimental multiple sclerosis drug BG-12 revealed no new safety concerns, and showed similar efficacy when given twice or three times a day, according to a summary of results to be presented at an upcoming conference.

Initial results from the trial, known as DEFINE, were released in April and showed the drug, when given twice a day, cut the annualized relapse rate by 53 percent ...

Can Biogen Idec keep the hits coming? The biotech giant's stock has been at the top of the charts among its peers over the past year, helped considerably by its experimental multiple sclerosis drug BG-12's performance in late-stage development.

With new Phase III data on the potential blockbuster expected within weeks, analysts told Reuters about some of the key factors that could play a role in the success of oral drug in the MS ...

A Phase 3 trial of Biogen Idec Inc.'s multiple sclerosis treatment BG- 12 met the primary endpoint of reducing the number of patients who relapsed at two years when compared with a placebo.

The investigational oral compound, dimethyl fumarate, also met secondary targets, including lower ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1679

Just tickled with some of the stuff that hits the inbox on a daily basis. Highly recommend all to sign up for google news alerts, with keywords multiple sclerosis and another one for ccsvi. It's like having a front row seat to the news cycle as it happens.

Fumaric salts have been used to treat psoriasis, and now, it appears the anti-oxidative effects that help that condition, also may help MS sufferers, and Biogen is ...

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.

BG-12, an immunomodulatory agent, reduces frequency of new gadolinium-enhancing (Gd+) lesions in relapsing multiple sclerosis (MS). This study reports the effect of 240 mg BG-12 orally three times daily (tid) for 24 weeks on the evolution of new Gd+ lesions to T1-hypointense lesions.

Brain magnetic resonance imaging (MRI) scans from patients in placebo and 240 mg BG-12 tid arms ...

Anyone heard about this


<shortened url>

BG-12 significantly reduced brain lesions in multiple sclerosis 24 October 2008

Biogen Idec announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting multiple sclerosis (MS) when in comparison to therapy with placebo (p<0.0001).

The data also showed a 53 percent reduction in the ...

I've been taking fumaric acid 240mg 3x a day for four months to treat PPMS. I feel like something positive is happening to my immune system, I'm just not sure what. Does anyone know what the mechanism of BG-12 is supposed to be? Any one in a trial??

I have been faithfully taking fumaric acid for two months now --240mg TID.
The good news to report is that I have had absolutely no adverse effects so far and I'm feeling better -- less fatigue, normal workload, able to exercise like I want, not as overwhelmed with simple tasks, etc. It's tough for me to tell whether it's the antibiotics or the fumaric acid helping me. What I would like to see is improvement ...

Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple Sclerosis

Biogen Idec announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS).

The DEFINE (determination of the efficacy and safety of oral fumarate in relapsing-remitting MS) and CONFIRM (comparator and an oral fumarate in relapsing-remitting MS) studies will include more than 2,000 total patients in North America, ...